It has been revealed that MALAT1 can promote angiogenesis, thereby accelerating the development and metastasis of HCC, indicating that targeting the MALAT1/miR-140/VEGF-A axis may be an effective way to treat HCC in the future [77]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.